assessed the efficacy of blinatumomab—an antibody with dual specificity for CD19 and CD3 antigens—in patients with non ... agent. Clinical trials that investigate the efficacy of bispecific ...

Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel ...

18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape ... accompanied by significant clinical advancements. According to recent data, more than 85% of bsAbs in clinical ...

(NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with ...

DUBLIN--(BUSINESS WIRE)--The "Bispecific Antibody & Cancer Patent Landscape ... accompanied by significant clinical advancements. According to recent data, more than 85% of bsAbs in clinical ...

This trial aims to evaluate the clinical potential of CS2009 in a wide range of advanced solid tumors including, but not limited to, non-small cell ... trispecific antibody designed and developed ...

We are on track for an IND filing in the third quarter of this year and are excited to begin generating data with the first-ever DR3 blocking antibody to enter clinical trials. Shattuck remains ...

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.